NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease

SAN FRANCISCO, CA, USA I May 21, 2021 I Nurix Therapeutics, Inc.(Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data from its NX-5948 program will be presented at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress, which will be held June 2−5, 2021. In a collagen-induced arthritis (CIA) mouse model, administration of NX-5948, an orally bioavailable, small-molecule degrader of Bruton’s tyrosine kinase (BTK), led to robust improvement of arthritis symptoms compared to untreated controls. These data support clinical development of NX-5948 for the treatment of autoimmune diseases.

Abstract Number: POS0006
Title: NX-5948, a Selective Degrader of BTK, Significantly Reduces Inflammation in a Model of Autoimmune Disease
Session Title: Adaptive immunity (T cells and B cells) in rheumatic diseases
Poster Number: 1675

A copy of the abstract can be found on the EULAR Congress website.

About NX-5948
NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK that has been designed to lack IMiD activity for potential applications in indications where sparing IMiD activity may be beneficial. Nurix is investigating development of NX-5948 for the potential treatment of certain autoimmune diseases as well as certain B-cell malignancies.

About Nurix Therapeutics, Inc.  
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

SOURCE: Nurix Therapeutics